



## Theraclion announces the start of clinical trials for accelerated procedure

**Malakoff – July 15<sup>th</sup>, 2015 – THERACLION** (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, today announced that it has initiated a clinical trial intended to validate the performance of its new Echopulse® procedure. The proprietary technology enables significantly faster treatment delivery.

The trial was launched on June 18<sup>th</sup> and nine patients have been enrolled to date. Both thyroid nodules and breast fibroadenoma have been treated and as expected, workflow has been accelerated three-fold. *“These first treatments with the new procedure have been very promising as they were not only faster but were also a much more pleasant experience for both the patient and the physician,”* said Professor Roussanka Kovatcheva of the University Hospital of Endocrinology of Sofia, Bulgaria.

*“The start of this new trial demonstrates Theraclion’s commitment to developing breakthrough treatment solutions. It is also based upon the company’s strong intellectual property,”* added Sylvain Yon, deputy CEO and VP for R&D of Theraclion.

*“Treatment acceleration has been a major angle of our product development strategy. In-time delivery of the announced milestones is a firm commitment to our customers and shareholders. We aim to develop HIFU (high intensity focused ultrasound) thermal ablation systems that perform at a level that is unmatched in the industry. This technology will significantly increase our physician adoption rate around the world,”* said David Caumartin, CEO of Theraclion.

### About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 25 people, 52 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: [www.theraclion.com](http://www.theraclion.com).

**Theraclion is listed on Alternext Paris**  
**PEA-PME Eligible**  
**Mnemonic: ALTHE - ISIN Code: FR0010120402**



## **Contacts:**

### **Theraclion**

David Caumartin

CEO

Tel.: +33 (0)1 55 48 90 70

[david.caumartin@theraclion.com](mailto:david.caumartin@theraclion.com)

### **NewCap**

Financial Communications & Investors relations

Emmanuel Huynh / Valentine Brouchet

Tel.: +33 (0)1 44 71 94 94

[theraclion@newcap.fr](mailto:theraclion@newcap.fr)

### **Kalima**

Press Relations

Estelle Reine-Adélaïde/ Florence Calba

Tel. : + 33 (0)1 44 90 82 54

[era@kalima-rp.fr](mailto:era@kalima-rp.fr)